Li Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Li Tan has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Dongmei Zhao
Department of Human Anatomy, School of Basic MedicalScience, Binzhou Medical University, Yantai, China
1 shared publication Guo Yu
Reproduction Centre, The Second Affiliated Hospital of Zhengzhou University Zhengzhou City Henan Province China
1 shared publicationLijing Wan
Reproduction Centre, The Second Affiliated Hospital of Zhengzhou University Zhengzhou City Henan Province China
1 shared publication- Liying Ma
National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, National Center for AIDS/ STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
1 shared publication Meng Wang
Reproduction Centre, The Second Affiliated Hospital of Zhengzhou University Zhengzhou City Henan Province China
1 shared publicationPeng-Fen Li
Department of Reproductive Medicine, Second Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
1 shared publication
Latest Publications
- Open Access
- 20 November 2023
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 90 (6) , e13795
Naringenin alleviates the excessive lipid deposition of polycystic ovary syndrome rats and insulin‐resistant adipocytes by promoting PKGIα
Background: Naringenin (NGEN) has anti‐inflammatory and anti‐diabetic effects. On this basis, this study aims to determine whether NGEN affects insulin resistance (IR) in polycystic ovary syndrome (PCOS).Methods: CCK‐8 assay and oil red O staining were used to detect the cytotoxicity of NGEN and lipid production in cells or tissues, respectively. The differentiated mature SW872 cells were treated with palmitic acid (PA) to mimic IR cell model. Through detecting glucose consumption, the changes of inflammation and glycolipid metabolism can be observed with the assessment on expression levels of the inflammatory factors as well as lipid synthesis‐ (ACC, SREBP1c, PPARγ), glucose metabolism‐ and thermogenesis (ATGL, GLUT4, UCP1)‐related genes. Insulin sensitivity was determined by changes in glucose consumption and PKGIα pathway. PKGIα was silenced to verify the protective mechanism of NGEN. PCOS rat model was constructed to confirm the results of cell experiments in vivo.Results: NGEN generated no effect on SW872 cell viability. SW872 cells were differentiated and mature, as evidenced by lipid droplet formation, lipid synthesis gene activation, sugar metabolism and inhibition of thermogenesis‐related genes. PA induction promoted lipid synthesis in mature adipocytes, and inhibited glucose metabolism and cell insulin sensitivity. NGEN pretreatment effectively alleviated the above‐mentioned abnormalities. The protective mechanism of NGEN was achieved through promoting PKGIα activation. NGEN also mitigated the abnormal glucose and lipid metabolism in PCOS rats.Conclusion: NGEN inhibits the expression of PKGIα to alleviate IR that occurs in PCOS.
- 20 November 2023
- Published by Wiley in American Journal of Reproductive Immunology
- Vol. 90 (6) , e13795
Open AccessNaringenin alleviates the excessive lipid deposition of polycystic ovary syndrome rats and insulin‐resistant adipocytes by promoting PKGIα
Background: Naringenin (NGEN) has anti‐inflammatory and anti‐diabetic effects. On this basis, this study aims to determine whether NGEN affects insulin resistance (IR) in polycystic ovary syndrome (PCOS).Methods: CCK‐8 assay and oil red O staining were used to detect the cytotoxicity of NGEN and lipid production in cells or tissues, respectively. The differentiated mature SW872 cells were treated with palmitic acid (PA) to mimic IR cell model. Through detecting glucose consumption, the changes of inflammation and glycolipid metabolism can be observed with the assessment on expression levels of the inflammatory factors as well as lipid synthesis‐ (ACC, SREBP1c, PPARγ), glucose metabolism‐ and thermogenesis (ATGL, GLUT4, UCP1)‐related genes. Insulin sensitivity was determined by changes in glucose consumption and PKGIα pathway. PKGIα was silenced to verify the protective mechanism of NGEN. PCOS rat model was constructed to confirm the results of cell experiments in vivo.Results: NGEN generated no effect on SW872 cell viability. SW872 cells were differentiated and mature, as evidenced by lipid droplet formation, lipid synthesis gene activation, sugar metabolism and inhibition of thermogenesis‐related genes. PA induction promoted lipid synthesis in mature adipocytes, and inhibited glucose metabolism and cell insulin sensitivity. NGEN pretreatment effectively alleviated the above‐mentioned abnormalities. The protective mechanism of NGEN was achieved through promoting PKGIα activation. NGEN also mitigated the abnormal glucose and lipid metabolism in PCOS rats.Conclusion: NGEN inhibits the expression of PKGIα to alleviate IR that occurs in PCOS.
- 1 January 2022
- Vol. 53 (1) , 133-136
[Influencing Factors of Pregnancy Outcome of in vitro Fertilization-Embryo Transfer].
To analyze the effect of factors relevant to blastocyst transfer on the pregnancy outcome of in vitro fertilization-embryo transfer (IVF-ET). The clinical data of 790 pregnant women who underwent IVF-ET in our hospital from July 2015 to July 2020 were retrospectively analyzed. The pregnancy outcome of blastocysts transferred on day 5 (D5, n=705) and those transferred on day 6 (D6, n=85) were compared. According to the pregnancy outcome, the cases were divided into a live birth group ( n=322) and a non-live birth group ( n=468), and multivariate logistic regression was conducted to study the effect of factors relevant to blastocyst transfer on the live birth outcome of IVF-ET. In the D5 group, the biochemical pregnancy rate, clinical pregnancy rate and live birth rate of blastocyst transfer were 69.93%, 64.96%, and 41.84%, respectively, which were significantly higher than those of the D6 group at 50.59%, 45.88%, and 30.59%, respectively. The difference was statistically significant ( P0.05). Multivariate logistic analysis revealed that age>35 years, years of infertility>5 years, endometrium thicknessP<0.05). The adverse pregnancy outcomes of IVF-ET were found to be associated with age, duration of infertility, endometrial thickness on the day of to blastocyst transfer, trophoblast cell rating, and blastocyst transfer performed after how many days of embryo development, and multiparity, which should be closely monitored, and effective measures should be adopted accordingly to prevent adverse outcomes of pregnancy.
- 1 January 2022
- Vol. 53 (1) , 133-136
[Influencing Factors of Pregnancy Outcome of in vitro Fertilization-Embryo Transfer].
To analyze the effect of factors relevant to blastocyst transfer on the pregnancy outcome of in vitro fertilization-embryo transfer (IVF-ET). The clinical data of 790 pregnant women who underwent IVF-ET in our hospital from July 2015 to July 2020 were retrospectively analyzed. The pregnancy outcome of blastocysts transferred on day 5 (D5, n=705) and those transferred on day 6 (D6, n=85) were compared. According to the pregnancy outcome, the cases were divided into a live birth group ( n=322) and a non-live birth group ( n=468), and multivariate logistic regression was conducted to study the effect of factors relevant to blastocyst transfer on the live birth outcome of IVF-ET. In the D5 group, the biochemical pregnancy rate, clinical pregnancy rate and live birth rate of blastocyst transfer were 69.93%, 64.96%, and 41.84%, respectively, which were significantly higher than those of the D6 group at 50.59%, 45.88%, and 30.59%, respectively. The difference was statistically significant ( P0.05). Multivariate logistic analysis revealed that age>35 years, years of infertility>5 years, endometrium thicknessP<0.05). The adverse pregnancy outcomes of IVF-ET were found to be associated with age, duration of infertility, endometrial thickness on the day of to blastocyst transfer, trophoblast cell rating, and blastocyst transfer performed after how many days of embryo development, and multiparity, which should be closely monitored, and effective measures should be adopted accordingly to prevent adverse outcomes of pregnancy.